Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.52 |
| ▸ | IDH1 | O75874 | 2/20 | 0.51 |
| ▸ | IDH2 | P48735 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701454 | 0.81 | IDH1 (0.52) | GPR119IDH1IDH2HRH3TGFBR1 | |
| SCHEMBL21607890 | 0.80 | IDH1 (0.49) | GPR119IDH1IDH2TGFBR1 | |
| SCHEMBL3025368 | 0.80 | IDH1 (0.51) | GPR119IDH1IDH2HRH3DPP4 | |
| SCHEMBL3036171 | 0.79 | IDH1 (0.50) | GPR119IDH1IDH2HRH3TGFBR1 | |
| SCHEMBL14701443 | 0.78 | GPR119 (0.58) | GPR119DPP4TGFBR1 | |
| SCHEMBL26081091 | 0.76 | IDH1 (0.51) | IDH1IDH2HRH3TGFBR1 | |
| SCHEMBL26081092 | 0.76 | IDH1 (0.49) | IDH1IDH2HRH3TGFBR1 | |
| SCHEMBL15391254 | 0.75 | GPR119 (0.53) | GPR119IDH1IDH2HRH3 | |
| SCHEMBL27158820 | 0.75 | IDH1 (0.52) | GPR119IDH1IDH2TGFBR1 | |
| SCHEMBL2145808 | 0.75 | IDO1 (0.48) | GPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | GPR119 136/4885IDH1 2032/4885IDH2 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.